Q-omics provides the consensus-scored ATP8A2P3 profile across patient tissues and cancer cell-line models. ATP8A2P3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ATP8A2P3 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, ATP8A2P3 RNA expression shows 6,774 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, BLCA, and STAD as cancer lineages where ATP8A2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP8A2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP8A2P3 survival associations across molecular data types. ATP8A2P3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP8A2P3 RNA expression–survival associations across cancer types. High ATP8A2P3 expression shows unfavorable associations in UCEC, ACC, THCA and CESC, but favorable associations in UCS and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UCEC as the clearest survival context for ATP8A2P3 RNA expression.
This table summarizes ATP8A2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ATP8A2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP8A2P3 shows higher tumor expression in BLCA, KIRC, KIRP and COAD. The BLCA box plot shows higher ATP8A2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .010).
This table shows molecular features associated with ATP8A2P3 in patient tissues and cancer cell lines. In patient samples, ATP8A2P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
